211results about How to "Reverse drug resistance" patented technology

The invention discloses an application of nanometer structure lipid carrier administration system in the antineoplastic drug to reverse the multiple-drug tolerance of tumour cell, which comprises the following parts: solid lipid material, liquid lipid material and antineoplastic drug, wherein the rate of the liquid lipid (such as oleic acid) is 0-30wt%; the solid lipid is selected from monoglyceride; the liquid lipid is oleic acid; the antineoplastic drug is Paclitaxel or adriablastina. The invention has highly effective cell uptaking and cytolymph condensing function with packing molecular target in the antineoplastic drug of cell, which avoids P-glucoprotein in the drug tolerant cytolymph from identifying the antineoplastic drug to reduce exclusion.

The invention relates to a tumor-targeted sound and light power medicine-carrying nanometer nano-micelle, and a preparation method and a purpose thereof. The medicine-carrying nanometer nano-micelle is structurally characterized in that porphyrins compounds and anthracyclines chemotherapeutic medicine form a nanometer composition through a pi-pi conjugation effect; and amphiphilic block copolymers with PEO (polyoxyethylene) or PEG (polyethylene glycol) hydrophilic segments cover nanometer compounds through the hydrophobic effect to form a hydrophilic case. The medicine-carrying nanometer nano-micelle is in a regular spherical form, and has the advantages of uniform distribution, stable property and high medicine carrying capacity; the medicine can be conveyed to the tumor focus in the targeted way and can be effectively enriched in the tumor tissue; under the ultrasound (illumination) condition, the treatment effect of the anthracyclines chemotherapeutic medicine on the tumor can be obviously enhanced; and the tumor drug resistance can be effectively reversed. Wide clinic application prospects can be realized in an aspect of combined tumor treatment by a sound (light) power therapy method and chemotherapy.

The invention relates to PLGA ultrasonic nano bubbles integrating ultrasonic imaging, drug delivery and gene therapy into a whole and a preparation method thereof. The preparation method comprises the following steps: preparing drug-loading nano bubbles loaded with a chemotherapy drug DOX, further modifying PLGA nano bubbles through PEI, adsorbing shRNA plasmids of MDR-1, thereby forming the composite nano bubbles. The nano bubbles have high drug loading rate and encapsulation efficiency, drug release has pH responsiveness, the loaded genes can be protected, expression of drug resistance genes MDR-1 is effectively silenced, the ultrasonic imaging capacity can be exerted, and the drugs and genes can be simultaneously and efficiently delivered to tumor locations to exert a synergistic effect.

The invention provides the application of a polymer system based on beta-cyclodextrin in P-glycoprotein of suppressive tumour cells. The polymer consists of the beta-cyclodextrin and grafted amphipathy polymer. The star-shaped amphipathy polymer based on beta-CD and provided by the invention has remarkable effect of restraining P-gp protein, and the restraining effect thereof is obviously superior to the inhibitor CsA of the P-gp protein. The polymer of the invention has the characteristics of low cytotoxicity, good biocompatibility, biodegradability, long intracorporeal circulation time and the like, and provides an ideal dose carrier material for hydrophobic antineoplastic agents.

The invention relates to an Acalypha australis L. and beta-lactam antibacterial medicine containing compound medicine for livestock and poultry. The compound medicine comprises the following raw materials in parts by weight: 3-30 parts of beta-lactam antibacterial medicine and 5-200 parts of Acalypha australis L, wherein the beta-lactam antibacterial medicine is amoxicillin, ceftriaxone sodium or ceftiofur sodium. Studies prove that after Acalypha australis L. is added to the antibacterial medicine, the resistance of bacteria to the antibacterial medicine can be reversed, thus improving the treatment effects of the antibacterial medicine. By preparing the compound medicine into powder, tablets, oral liquid or granules according to conventional methods and adding the compound medicine to feeds for livestock and poultry according to the additive amount of 0.1-7g of main medicine/kg of feed to feed the livestock and poultry, the medicine cost and the medicine residues can be substantially reduced, higher economic benefits can be created for farmers, and food safety is simultaneously ensured.

The invention belongs to the technical field of biological medicine and relates to a novel methotrexate (MTX)-Pluronic copolymer mixed micelle carrying an indissoluble medicament and a preparation method thereof. The method comprises the following steps of: performing chemical connection and copolymerization on Pluronic and MTX to obtain an MTX-Pluronic copolymer; and mixing the MTX-Pluronic copolymer with Pluronic-kind matters to prepare an MTX-Pluronic copolymer mixed micelle system, wherein a hydrophobic core of the mixed micelle carries the indissoluble medicament. Tests prove that the mixed micelle can improve the medicament-loading capacity of the indissoluble medicament, effectively reverses the medicament tolerance of tumors and has the medicament-delivery characteristic targeting folate receptors.

The invention discloses an adriamycin nano drug delivery system as well as a preparation method and application thereof. The drug delivery system comprises the following components in percentage by weight: 0.02%-1.5% of active ingredient containing adriamycin, 1%-20% of solid lipid, 0.1%-20% of liquid lipid, 0.5%-20% of emulsifier and 0.1%-5% of isoosmotic adjusting agent, wherein the solid lipid and the liquid lipid form nanoparticles to cover the active ingredient containing the adriamycin. The preparation method comprises the following steps: (1), uniformly dispersing the active ingredient containing the adriamycin, the solid lipid, the liquid lipid and fat-soluble emulsifier in an organic solvent, evaporating the organic solvent to obtain an oil phase; (2), uniformly dispersing other emulsifiers and the isoosmotic adjusting agent in water to obtain a water phase; (3), adding the water phase into the oil phase for emulsifying drop by drop; (4), homogenizing under high pressure; (5), cooling and degerming. The adriamycin nano drug delivery system disclosed by the invention can be used for realizing co-transporting of the adriamycin and a chemosensitizer, so that the killability of the adriamycin on liver cancer cells is strengthened.

Disclosed is an anticancer tumour extinguishing toxin expelling decoction, which is prepared from Chinese medicinal herbs including toad, Eupolyphaga Sinensis Walker, leeches, cantharis, house lizard, astragalus root, gen-seng, ganoderma lucidum, notoginseng, white atractylodes rhizome, burred tuber, zedoary, peach kernels, safflower and Oldenlandis.

The present invention provides a PEGylated and fatty acid grafted chitosan oligosaccharide comprising a structural unit represented by the following Formula (I) and a structural unit represented by the following Formula (II) and synthesize method, wherein the chitosan oligosaccharide has a molecular weight of less than 200,000 Da, and a degree of deacetylation of 70%-100%, and part of free amino groups of chitosan oligosaccharide chain are replaced by a fatty acid or PEG, where n refers to degree of polymerization of the PEG, and R is an alkyl group having 11-21 carbon atoms. The grafting ratio of fatty acids is 1%-50%, and the grafting ratio of PEG is 0.05%-50%. The present invention also comprise a pharmaceutical composition comprising the PEGylated and fatty acid grafted chitosan oligosaccharide as a carrier, and use of the PEGylated and fatty acid grafted chitosan oligosaccharide in preparation of a pharmaceutical composition.

The invention relates to a herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry. The compound composition is prepared from the following raw materials in parts by weight: 3 to 30 parts of antibacterial drugs, and 5 to 200 parts of herba lycopi. The raw materials are uniformly mixed to prepare powder, tablets, oral liquid or granules which are added into animal feed in a ratio of 0.1 to 5g/kg feed addition amount for feeding, and the drug resistances of bacteria to the antibacterial drug can be reversed, so that the treatment effect of antibacterial drugs can be improved, the administration cost can be greatly reduced, and higher economic benefit can be created for farmers.

The invention relates to an Acalypha australis L. and amikacin containing compound medicine for livestock and poultry. The compound medicine comprises the following raw materials in parts by weight: 3-30 parts of amikacin and 5-200 parts of Acalypha australis L. Studies prove that after Acalypha australis L. is added to an antibacterial medicine, the resistance of bacteria to the antibacterial medicine can be reversed, thus improving the treatment effects of the antibacterial medicine. By preparing the compound medicine into powder, tablets, oral liquid or granules according to conventional methods and adding the compound medicine to feeds for livestock and poultry according to the additive amount of 0.1-7g of main medicine/kg of feed to feed the livestock and poultry, the medicine cost and the medicine residues can be substantially reduced, higher economic benefits can be created for farmers, and food safety is simultaneously ensured.

The invention relates to a creat/amikacin-containing compound medicine for livestock and fowl, which is prepared from the following raw materials in parts by weight: 7-30 parts of amikacin and 10-160 parts of creat. The raw materials are evenly mixed and prepared into powder, tablets, oral liquids or granules, and 0.1-7g of the compound medicine is added to every kilo of feed for livestock and fowl for feeding; and the feed with the compound medicine can reverse the drug resistance of bacteria to antibacterial agents, thereby enhancing the treatment effect of the antibacterial agents, greatly lowering the medicine cost and medicine residue, creating higher economic benefit for farmers and ensuring the human food safety.

The invention discloses an antineoplastic combined drug, and applications thereof in preparation of anticancer drugs. The antineoplastic combined drug comprises, by weight, 10 to 40 parts of a first reagent and 2 to 40 parts of a second reagent. The invention also discloses applications of chlorogenic acid in preparing anticancer drug toxic and side effect inhibitors. EGFR is taken as the target point of the anticancer drugs. According to the applications, the targeting performance of the anticancer drugs in treatment of non-small cell carcinoma, breast cancer, malignant gliomas, and nasopharyngeal carcinoma is improved, the toxic and side effect is reduced, and generation resistance on the drugs taking EGFR as the target point is delayed.

The invention relates to a compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry. The compound medicine comprises the following raw materials in parts by weight: 3 to 20 parts of florfenicol and 10 to 180 parts of herba lycopi. The raw materials are uniformly mixed to be prepared into powder, tablets, an oral liquid or granules to be added into livestock and poultry feed according to the additive amount of 0.1-5 g/kg for feeding, and drug resistance of antibacterial on bacteria can be reversed, so that the treatment effect of the antibacterial can be improved, the medicine cost can be greatly reduced, and higher economic benefits are created for farmers.

The invention relates to an Acalypha australis L. and mequindox containing compound medicine for livestock and poultry. The compound medicine comprises the following raw materials in parts by weight: 3-30 parts of mequindox and 5-200 parts of Acalypha australis L. Studies prove that after Acalypha australis L. is added to an antibacterial medicine, the resistance of bacteria to the antibacterial medicine can be reversed, thus improving the treatment effects of the antibacterial medicine. By preparing the compound medicine into powder, tablets, oral liquid or granules according to conventional methods and adding the compound medicine to feeds for livestock and poultry according to the additive amount of 0.1-7g of main medicine/kg of feed to feed the livestock and poultry, the medicine cost and the medicine residues can be substantially reduced, higher economic benefits can be created for farmers, and food safety is simultaneously ensured.

The invention relates to an Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry. The compound medicine comprises the following raw materials in parts by weight: 3-30 parts of sulfamonomethoxine sodium and 5-200 parts of Acalypha australis L. Studies prove that after Acalypha australis L. is added to an antibacterial medicine, the resistance of bacteria to the antibacterial medicine can be reversed, thus improving the treatment effects of the antibacterial medicine. By preparing the compound medicine into powder, tablets, oral liquid or granules according to conventional methods and adding the compound medicine to feeds for livestock and poultry according to the additive amount of 0.1-7g of main medicine/kg of feed to feed the livestock and poultry, the medicine cost and the medicine residues can be substantially reduced, higher economic benefits can be created for farmers, and food safety is simultaneously ensured.

The invention relates to an Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry. The compound medicine comprises the following raw materials in parts by weight: 3-30 parts of fosfomycin and 5-200 parts of Acalypha australis L. Studies prove that after Acalypha australis L. is added to an antibacterial medicine, the resistance of bacteria to the antibacterial medicine can be reversed, thus improving the treatment effects of the antibacterial medicine. By preparing the compound medicine into powder, tablets, oral liquid or granules according to conventional methods and adding the compound medicine to feeds for livestock and poultry according to the additive amount of 0.1-7g of main medicine/kg of feed to feed the livestock and poultry, the medicine cost and the medicine residues can be substantially reduced, higher economic benefits can be created for farmers, and food safety is simultaneously ensured.

The invention relates to a medicine composition for reversing cancel cell tolerance and application of the medicine composition, and particularly discloses an isocorydin (ICD) and a pharmaceutically acceptable novel use of salt of the isocorydin (ICD), which are used for preparing the medicine composition for treating cancer. The medicine composition can increase sensitivity of cancer cells to anti-cancer medicines, or reduce cancel cell tolerance to the anti-cancer medicines.

The invention discloses a preparation method of tumor-targeting aptamer-modified drug gene co-transport nanoparticles and application of the nanoparticles in preparation of EGFR-mutation-resistant drugs for lung cancer. The preparation method comprises the specific steps that firstly, Apt carboxyl is activated first and then reacted with amino on the surface of PAMAM, an Apt-PAMAM carrier is synthesized, the drug ERL is encapsulated to form an Apt-PAMAM/ERL nano-drug, and the Apt-PAMAM/ERL nano-drug is compounded with SUV to form a tumor-targeting nano-composite. By means of the composite, thedefect that the ERL is poor in water solubility is overcome, and meanwhile, the surface-modified Apt and ERL dual-targeting EGFR mutation tumor cells are utilized so as to increase targeting of tumortissue; through compounding with the SUV, expression of anti-apoptosis genes is silenced, the drug resistance of the cells to the ERL is reversed, therefore, the bioavailability of the drug is effectively improved, and the clinical application value of the drug is improved.

The invention relates to a red paeonia/amikacin-containing compound medicine for livestock and fowl, which is prepared from the following raw materials in parts by weight: 3-30 parts of amikacin and 5-200 parts of red paeonia. The inventor utilizes the red paeonia and antibacterial agent to constitute the compound medicine. The research proves that after the red paeonia is added into the antibacterial agent, the drug resistance of bacteria to the antibacterial agent can be reversed, thereby enhancing the treatment effect of the antibacterial agent. The compound medicine can be prepared into powder, tablets, oral liquids or granules by a conventional method, and 0.1-7g of the main medicine is added to every kilo of feed for livestock and fowl for feeding; and the feed with the compound medicine can greatly lower the medicine cost and medicine residue, create higher economic benefit for farmers and ensure the food safety.

The invention relates to a long-chain non-coding RNA PRALR, and an expression plasmid and a use thereof. Starting from TCONS-00013523 sequence, a complete gene sequence is discovered by 5'-RACE and 3'-RACE technologies and is named as PRALR (paclitaxel resistance-associated lncRNA, paclitaxel resistance-associated long-chain non-coding RNA). Then, the PRALR expression plasmid and siRNA are constructed, and the PRALR is further confirmed to be a novel ovarian cancer drug resistance-associated lncRNA; the constructed PRALR expression plasmid can significantly increase the expression quantity ofthe PRALR, and the designed siRNA can significantly reverse drug resistance of paclitaxel-resistant ovarian carcinoma cells. A powerful tool is provided for study of the mechanism of paclitaxel resistance and other chemotherapeutic drug resistance, and a reference is provided for clinical development of drugs to reverse the drug resistance of tumor to paclitaxel.

The invention relates to a compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry. Raw materials of the compound medicine comprise, by weight, 3-30 parts of the fluoroquinolones antibacterial drug and 5-200 parts of the radix paeoniae rubrathe, wherein the fluoroquinolones antibacterial drug is norfloxacin, ciprofloxacin or levofloxacin. According to a research result, drug resistance of bacteria to the antimicrobial medicine can be inverted since the radix paeoniae rubrathe is added to the antimicrobial medicine, so that the treatment effect of the antimicrobial medicine is improved. The compound medicine, which is manufactured into a powder, a tablet, an oral liquid or a particulate agent through a conventional method, is added to livestock and poultry feed for feeding the livestock and poultry with an addition amount being 0.1-7g of a main drug per kilogram of feed. Medicine cost and medicine residue can be reduced greatly, breeding farmers obtain a higher economic benefit and meanwhile foodstuff safety is ensured.